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1. Introduction 
Cytochrome P450 enzymes (CYP) play a pivot role in phase I of xenobiotic 
biotransformation. Many of CYP enzymes are known to be polymorphic, with many allelic 
variants. As a consequence of huge number of possible allele combinations, a wide range of 
metabolic activity can be observed among patients in population. Individual CYP activity 
may be also affected by various xenobiotics – either induction or inhibition of distinct CYP 
isoenzyme may cause failure or toxicity of pharmacotherapy. Due to this, some prediction of 
metabolic activity is worthwhile in clinical practice. This chapter is going to briefly 
summarize the possibilities of in vivo and in vitro CYP metabolic activity assessments of 
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 enzymes.  
2. In vivo enzyme activity assessment  
2.1 Clinical need for CYP phenotyping 
It is useful to assess CYP metabolic activity prior to or during the pharmacotherapy and to 
adjust the individual dosage according to the patient's phenotype at least in some cases.  
The best studied CYP enzyme concerning polymorphisms, enzyme inhibition and dosage 
individualization according to phenotype is probably CYP2D6, followed by CYP2C9 and 
CYP2C19. These enzymes are highly polymorphic, contrary to CYP3A4, where the 
metabolic activity may vary due to differences in CYP3A4 gene expression and 
pharmacokinetic interactions [Ingelman-Sundberg 2004]. Nevertheless, any shift in 
metabolic capacity of individual CYP enzyme may result either in decreased or increased 
therapeutic response or intensity of adverse effects. For example, after paroxetine 
administration to the patients on tamoxifen, a decrease in plasma levels of active metabolite 
of tamoxifen was detected [Stearns et al. 2003]. This can be crucially important in breast 
cancer treatment. On the other hand, CYP2D6 ultrarapid metabolizer phenotype may cause 
failure of pharmacotherapy due to the very low and thus ineffective drug plasma levels 
[Corruble 2008]. In antipsychotic treatment, an association has been observed between 
extrapyramidal adverse effects and CYP2D6 genotype [Fleeman et al. 2011]. Significant 
clinical consequences of CYP2D6 genotype or enzyme inhibition were described also in 
beta-blockers, antianginal, antiarrythmic drugs, antihistamines and antiemetics. The clinical 
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impact of enzyme polymorphism or changes due to inhibition or induction usually depends 
on the contribution of other CYP forms to the total drug's elimination. By this, the relative 
therapeutic potency of the parent drug or any of its metabolites may be altered [Zhou 2009]. 
Methodological approaches such as assessment of metabolic ratio of specific substrate to 
metabolite(s) in saliva, plasma / serum or urine are most widely used to assess metabolic 
activity in vivo. Besides determination of the concentrations of probe and metabolite in 
biological fluids, specific substrates are used in various breath tests. Rarely some other 
approaches are used, e.g. the pupilometry after opioid administration.  
It is essentially important to differentiate between in vivo and in vitro metabolic activity 
assessments, as they show very often discrepant results.  
One of the greatest advantages of genotype assessment is that it does not need to be 
repeated because it does not change with time or under the simultaneous influences of 
drugs and other factors. On the other side the disadvantage of the pharmacogenetic testing 
is, that genotype does not always correlate with observed metabolic activity recorded using 
probe drug(s). This discrepancy may be caused by various epigenetic factors as well as by 
inhibition or induction of enzyme metabolic activity caused by other xenobiotics 
coadministered. 
2.2 Conventional probe substrates for in vivo metabolic activity assessment 
Metabolic activity of various CYP enzymes is most often assessed using selective substrate 
of distinct CYP enzyme ("marker of metabolic activity"), i.e. a drug (or substance) which is 
ideally metabolized by the single CYP enzyme [Pelkonen et al. 1998, Pelkonen et al. 2008]. 
Ideal marker should be a non-toxic substance, with regard to its possible usage in vivo. 
Moreover, such ideal marker should be easily available substance (i.e. registered as a 
therapeutic drug), which is assessable in biological fluids together with its main 
metabolite(s). Pharmacokinetics of ideal marker should be determined by metabolism and 
not by intensity of liver perfusion, protein binding or elimination of unchanged drug [Frank 
et al. 2007, Kivisto & Kroemer 1997, Pelkonen et al. 1998]. Phenotype classification in vivo is 
based on the drug to metabolite concentration ratio in biological fluids (metabolic ratio): MR 
= [cdrug/cmetabolite]. With regard to the phenotype (or MR), metabolizers can be classified into 
4 different categories – poor metabolizers (PM), intermediate metabolizers (IM), extensive 
metabolizers (EM) and ultrarapid metabolizers (UM) [Zanger et al. 2004]. Bimodal or 
trimodal distribution of log-transformed MR is observed in some probe substrates. 
Histograms of log-transformed MR may refer to cut-off values of MR which distinguish EM 
from UM, PM or IM.. Doses of medication may be adjusted according to the current 
phenotype, following the principles of personalized medicine. Probe drugs with unimodal 
distribution of their MRs cannot reflect genetically encoded differences in the metabolism. 
Despite this, such probe substrates have also been used for CYP metabolic activity 
prognosis, but with varying degree of predictive success [Benet 2005]. Some of the probe 
drugs are metabolized by multiple CYPs, as observed in warfarin or caffeine [Kaminsky & 
Zhang 1997, Tassaneeyakul et al. 1994]. Moreover, metabolic fate of some substrates may be 
enantiomer specific: R-warfarin is primarily metabolized by CYP1A2 and CYP3A4, S-
warfarin by CYP2C9 [Kaminsky & Zhang 1997]. Despite this, the major metabolic pathway 
may serve as a tool for distinct isoenzyme metabolic activity assessment (S-warfarin for 
CYP2C9 phenotype assessment). Phenotype expressed as MR is basically determined by the 
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genotype, but may be also influenced by age [Kamali et al. 2004], sex [Nafziger et al. 1998], 
habits [Bozikas et al. 2004], co-medication and/or liver disease [Rost et al. 1995].  
The above mentioned principles are also utilized in drug development, where drugs are 
evaluated concerning their CYP-mediated interactions prior to the registration and launch 
on the basis of the enzyme-specific reaction [Zlokarnik et al. 2005].  
2.2.1 CYP1A2  
Many substrates have been tried for CYP1A2 metabolic activity assessment, but caffeine is 
the most widely used one, although other enzymes are involved in biotransformation of 
caffeine and its metabolites (xanthinoxidase, N-acetyl transferase and with lesser extent also 
CYP2E1, CYP2A6, CYP3A4, CYP3A5) [Dorne et al. 2001, Tassaneeyakul et al. 1994]. Many 
metabolic ratios were used in phenotyping studies, with "caffeine metabolic ratio" (CMR) as 
the well determined marker of CYP1A2 metabolic activity [Hakooz 2009]. On the other 
hand, simple paraxanthine to caffeine molar concentration ratio assessed in serum/plasma 
or saliva is also used [van Troostwijk et al. 2003]. Other substrates are used much rarely in 
phenotyping studies. Probes for CYP1A2 metabolic activity assessment are summarized in 
Table 1. Moreover, various concentration ratios of caffeine and its metabolites are also used 
for determination of NAT2 (arylamine N-acetyltransferase), CYP2A6 and xanthinoxidase 
metabolic activities [Begas et al. 2007, Hakooz 2009, Nyeki et al. 2001].  
 
Probe CYP1A2-specific reaction 
caffeine N-demethylation 
phenacetine O-deethylation 
theophylline N-demethylation 
Table 1. Probes for CYP1A2 metabolic activity assessment [Ou-Yang et al. 2000, Takata et al. 
2006] 
2.2.2 CYP2C9 
CYP2C9 is known to be polymorphic, with more than 40 alleles identified [Ingelman-
Sundberg et al. 2011]. Ten years ago it was thought that with CYP2C9 genotyping it will be 
possible to avoid adverse reactions in patients receiving warfarin [Ma et al. 2002]. These 
expectations were mostly calmed by reality, that CYP2C19 genotype is not the single major 
factor influencing warfarin toxicity.  
Most often used CYP2C9-specific reactions are summarized in the Table 2. Diclofenac 4’-
hydroxylation and tolbutamide methylhydroxylation [Zhou et al. 2009] seem to be the most 
frequently used, however, tolbutamide methylhydroxylation is also catalyzed by CYP2C19 
[Wester et al. 2000]. Phenotyping with the use of substrates with low therapeutic index 
(phenytoin, oral anticoagulants) would be unsafe since the enzyme activity in CYP2C9*3 
homozygotes is nearly absent, and these subjects could suffer from drug toxicities or 
adverse drug reactions [Zhou et al. 2009]. In vivo biotransformation of celecoxib, a 
cyclooxygenase (COX)-2 inhibitor, is affected by CYP2C9 polymorphisms [Guengerich 2005] 
and thus is object of interest as a potential probe substrate. CYP2C9 protein levels correlate 
with hexobarbital C3-hydroxylation activity [Kato et al. 1992] and Rendic mentions 
hexobarbital among CYP2C9 probe substrates [Rendic 2002] .  
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Probe CYP2C9-specific reaction 
diclofenac 4’-hydroxylation 
losartan oxidation 
phenytoin 4’-hydroxylation 
S-flurbiprofen 4’-hydroxylation 
S-warfarin 7-hydroxylation 
tolbutamide methylhydroxylation 
Table 2. Probes for CYP2C9 metabolic activity assessment [Zhou et al. 2009] 
2.2.3 CYP2C19 
Folowing CYP2D6 and CYP2C9, CYP2C19 is the third well investigated polymorphic drug-
metabolizing enzyme. CYP2C19 metabolizes many psychoactive drugs. Many of them are 
able to inhibit CYP2C19 metabolic activity. Probes for CYP2C19 metabolic activity 
assessment are summarized in Table 3. 
 
Probe CYP2C19-specific reaction 
chloroguanine 
(proguanil) 
conversion to cycloguanine 
omeprazole 5-hydroxylation 
S-mephenytoin 4'- hydroxylation 
Table 3. Probes for CYP2C19 metabolic activity assessment [FDA 2006, Nolin & Frye 2003, 
Tenneze et al. 1999] 
2.2.4 CYP2D6 
Suitable substrates for in vivo CYP2D6 phenotyping are listed in the Table 4. Among them, 
bufuralol and dextromethorphan are the most preferred substrates for in vitro preclinical 
studies [Zhou 2009]. Tramadol is metabolized to O-demethyltramadol (M1) by CYP2D6, but 
in studies in vitro was shown that M1 formation is mediated also by CYP2B6 in high extent. 
Moreover, correlation of tramadol/M1 metabolic ratio with MR of 
dextromethorphan/dextrorphan is modest and therefore tramadol use as a probe substrate 
is limited [Frank et al. 2007]. Since debrisoquine and sparteine are currently not available as 
registered drugs, dextromethorphan remains the most widely used probe drug for CYP2D6 
metabolic activity assessment in vivo [Zhou 2009].  
 
Probe CYP2D6-specific reaction 
codeine O-demethylation 
debrisoquine 4-hydroxylation 
dextromethorphan O-demethylation 
metoprolol α-hydroxylation 
sparteine dehydrogenation 
tramadol  O-demethylation 
Table 4. Probes for CYP2D6 metabolic activity assessment [Rasmussen et al. 1998, Rendic 
2002, Zanger et al. 2004, Zhou 2009].  
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2.2.5 CYP3A4 
CYP3A4 is the predominant enzyme of CYP3A subfamily and plays the pivot role in drug 
metabolism [Guengerich 2005]. Hepatic CYP3A4 metabolizes about 50 % of clinically used 
drugs [Guengrich 1999] and CYP3A4 is the most abundant intestinal CYP enzyme 
[Guengerich 2005]. CYP3A4 is not supposed to be polymorphic as e.g. CYP2D6, but CYP3A4 
activity may vary among individuals from 5 up to 50 fold [Ma et al. 2002]. Metabolic activity 
of CYP3A4 (expressed as log MR) has unimodal distribution; variation is probably a 
consequence of both genetic and non-genetic factors [Guengrich 1999, Ozdemir et al. 2000, 
Shimada et al. 1994, Wilkinson 1996]. Common probes for CYP3A4 metabolic ativity 
assessment are listed in the Table 5. 
 
Probe CYP3A4-specific reaction  
alfentanil demethylation 
alprazolam 4-hydroxylation 
codeine O-demethylation 
cortisol 6-β hydroxylation 
dapsone N-hydroxylation 
dextromethorphan N-demethylation 
erythromycin N-demethylation 
lidocaine N-deethylation 
midazolam 1-hydroxylation 
nifedipine oxidation 
quinidine 3-hydroxylation /N-oxidation 
testosterone 6-β hydroxylation 
triazolam 1-hydroxylation 
Table 5. Probes for CYP3A4 metabolic activity assessment [Liu et al. 2007, Rasmussen et al. 
1998, Rendic 2002, Wennerholm et al. 2005] 
Since none of suggested probes for CYP3A4 phenotyping is metabolized uniquely by this 
enzyme, and the active site of CYP3A4 is thought to be large and able to bind multiple 
substrates simultaneously, it is recommended to use at least 2 structurally unrelated probe 
substrates for precise enzyme activity evaluation [Ekroos & Sjogren 2006, Foti et al. 2010, Liu 
et al. 2007]. The apparent metabolic activity of CYP3A4 (assessed using probe substrates) 
may be affected by P-glycoprotein mediated decrease of availability of probe substrates 
[Guengerich 2005].  
By this, some authors suggest that there are no useful CYP3A4 substrates for accurate 
prediction of its metabolic activity [Benet 2005]. 
2.3 Differentiation between poor and extensive metabolizers: MR cut-off values 
2.3.1 CYP1A2 
Caffeine is the most frequently used probe drug and several metabolic ratios are used for 
CYP1A2 phenotyping. Urinary MR of (AFMU + 1U + 1X)/17U (also named as caffeine 
metabolic ratio, CMR) is probably mostly utilized [Campbell et al. 1987], followed by 
urinary MR of (17X + 17U)/137X [Muscat et al. 2008, Schrenk et al. 1998], salivary and 
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plasmatic MR of 17X /137X [Fuhr et al. 1996, Simon et al. 2001] or MR of (AFMU + 1U + 1X 
+ 17U + 17X)/137X in serum [Aklillu et al. 2003]. Due to several MRs used, there is not the 
only one, clear, and widely accepted MR cut-off value distinguishing poor and extensive 
metabolizers. Furthermore, bimodal or trimodal distribution of MR may be observed 
depending on the kind of ratio used [Muscat et al. 2008]. Using MR of (AFMU + 1U + 1X + 
17U + 17X)/137X in serum, log MR of 0.96 (corresponding MR = 9.12) was found to 
distinguish PM from EM [Aklillu et al. 2003]. Other authors assessed CYP1A2 phenotype 
using molar ratio of 17X/137X in the 4 h urine samples, and observed a bimodal distribution 
with a cut point of 1.85 separating poore and extensive phenotypes [Muscat et al. 2008]. 
Histograms of serum 17X/137X ratio indicated the antimode of 0.16 [Han et al. 2001].  
Metabolic ratio of AFMU/(AFMU +1U +1X) with an apparent antimode at 0.25 may serve 
for NAT2 phenotyping - subjects with metabolic ratios < 0.25 were then classified as slow 
acetylators and those with metabolic ratios > 0.25 as fast acetylators [Begas et al. 2007, 
Bendriss et al. 2000]. Some other authors suggest and use antimode of 0.34 of the same ratio 
[Nyeki et al. 2001, Tang et al. 1991]. 
Total salivary caffeine assessment (TOSCA) as a measure of general liver function was used 
for identification of patients with liver cirrhosis, with a cut-off value of 4.2 μg/ml, but 
TOSCA was not used for CYP1A2 phenotyping [Tarantino et al. 2006]. 
*abbreviations 
137X = 1,3,7 trimethylxanthine or caffeine 
17X = 1,7-dimethylxanthine or paraxanthine 
AFMU = 5-acetylamino-6-formylamino-3-methyluracil 
1U = 1-methyluric acid 
1X = 1-methylxanthine 
17U = 1,7-dimethyluric acid 
2.3.2 CYP2C9 
Phenytoin: Phenytoin hydroxylation index (amount of phenytoin administered/0-32 hr 
urinary output of hydroxyphenytoin) seems to be bimodaly distributed in population 
[Horsmans et al. 1997]. MR of 4-hydroxyphenytoin/phenytoin reveals a bimodal 
distribution although substantial overlap of this MR was seen between genetic variants of 
CYP2C9 [Aynacioglu et al. 1999]. Nevertheless, clear cut-off MR values are not suggested.   
Tolbutamide: Tolbutamide metabolism appears to be depend on CYP2C9 genotype [Lee et al. 
2005], but there was not suggested a clear MR (tolbutamide/4-hydroxytolbutamide) cut-off 
value to distinguish poor and extensive metabolizers. 
2.3.3 CYP2C19 
Omeprazole: Omeprazole is hydroxylated in position 5 to form 5-hydroxyomeprazole. A 
bimodal distribution of omeprazole to 5-hydroxyomeprazole metabolic ratio histograms and 
probit plots is observed. Using above mentioned MR, there was found antimode of 5.6 to 
distinguish between poor and extensive metabolizers in Chinese population [Wang et al. 
2007]. Different antimode of 12.0 distinguishing poor and extensive metabolizers was found 
when used MR of omeprazole + omeprazole sulfone /5'-hydroxyomeprazole [Rost et al. 1995]. 
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Mephenytoin: Both urinary 4-hydroxymephenytoin and the S/R enantiomer ratio of 
mephenytoin are able to discriminate between extensive and poor metabolizers [Wedlund et 
al. 1984]. In Chinese population sample, when S/R mephenytoin ratio was analyzed, probit 
plot suggested antimode of 0.8 distinguishing poor and extensive metabolizers [Demorais et 
al. 1995]. Antimode of 2 % of dose excreted as 4-hydroxymephenytoin has been used to 
distinguish poor and extensive metabolizers [Demorais et al. 1995]. An antimode of 1.0 in 
the log-mephenytoin hydroxylation index [log10 (μmol dose S-mephenytoin/μmol 4′-
hydroxymephenytoin excreted in 8-h urine], was used to classify the extensive and poor 
metabolizers [Yin et al. 2004]. 
Proguanil: Bimodal distribution of proguanil/cycloguanil MR was observed in Polynesian 
population with antimode of 10.0 [Wanwimolruk et al. 1998]. The same antimode was 
reported by Australian study [Coller et al. 1997]. 
2.3.4 CYP2D6 
Dextromethorphan: Eight-hour urinary MR of dextromethorphan to dextrorphan (conjugated 
+ unconjugated) with 0.3 as a cut-off value is well established and used to differentiate 
between extensive and poor metabolizers [Chladek et al. 2000, Ito et al. 2010, Lotsch et al. 
2009, O'Mathuna et al. 2008]. Urinary metabolic ratios based on free compounds (with an 
antimode of 4.0) also correlated with the conventional MR [Yeh et al. 2003]. Collection of 
urine during 8 hour (sometimes also 24 h) interval could be demanding process. Therefore 
alternative procedures have been developed for easier phenotyping. In addition to urine, 
saliva or plasma samples can also be used for the determination of MR [Chladek et al. 1997]. 
The serum MRDEM/DOR may serve as alternative tool for CYP2D6 phenotyping as also our 
results indicate tight correlation (r2 = 0.87) exists between MRDEM/DOR measured in serum 
(3h postdose) and MRDEM/DOR measured in urine (0-8 h postdose). Another approach has 
been tried for CYP2D6 phenotyping [Hu et al. 1998], in which a single or multiple-dose 
controlled-release dextromethorphan tablets were administered. It has been demonstrated 
that there is a good correlation between MR after single-dose and multiple-dose 
dextromethorphan as well as between MRs assessed in various kinds of samples [Hu et al. 
1998, Yeh et al. 2003]. Plasmatic (or serum) 3, 4 or 6 hour MRs and salivary 2, 3, 4, 5, 6 hour 
MRs were investigated regarding possibility to discriminate EM from PM and alternatively 
also from IM [Frank et al. 2007]. However, only 3 studies have determined the cut-off values 
for plasma or serum MR, namely those of Shiran et al. who determined the value of 0.1 for 
differentiating between EM and PM (using 3-hour postdose MRDEM/DOR)[Shiran et al. 2003]. 
The others, observed antimode of 2.0 to delineate EM from IM (using any time point in 
steady state) [Yeh et al. 2003], and Kohler et al. found the intercept separating EM from PM 
to be 0.126 (1-hour postdose MRDEM/DOR) [Kohler et al. 1997]. These results are in accordance 
with our results showing a cut-off found for serum MRDEM/DOR to discriminate between 
poor metabolizers from either extensive or extensive+intermediate metabolizers, but not for 
serum MRDEM/DOR to discriminate extensive metabolizers from intermediate metabolizers. 
On the other hand, it has been suggested, that it is not possible to delineate EM from IM 
using plasma MR [Hu et al. 1998]. In conclusion, there is a lack of evidence for clear 
plasma/serum or saliva dextromethorphan MR cut-off values. As the most used and best 
proved remains the urinary 0 - 8 h dextromethorphan to dextrorphan MR [Frank et al. 2007], 
but alternative procedures for phenotyping may be usefull in some groups of patients. 
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Debrisoquine: MR of debrisoquine/4-OH debrisoquine in urine collected for 8 hours serves as 
a well proved determinant of metabolic status: a bimodal distribution was observed in 
Caucasian population with antimode of 12.6 separating EM (MR < 12.6) from PM (MR > 
12.6) [Eiermann et al. 1998, Sachse et al. 1997]. For debrisoquine, there is not recommended 
any other sampling interval or other way of phenotypization except of urine 0 - 8h MR. 
Sparteine: MR of sparteine/sum of dehydrosparteines in urine collected 0 - 6 h post-dose is 
used for phenotype assessment, with 20.0 as the conventional cut-off point between PM and 
EM subjects [Basci et al. 1994, Paar et al. 1997]. This value was suggested to be slightly 
modified to 14.0 in another study [Halling et al. 2005]. 
2.3.5 CYP3A4 
There is a lack of evidence for existence of a bimodal distribution of CYP3A4 activity and 
therefore there is no consensus for antimode or cut-off values in any of used probe 
substrates.  
2.4 Breath tests and other approaches for CYP enzyme activity assessment 
Erythromycine breath test (EBT) is probably one of the best proved models for CYP3A4 
activity assessment. The hepatic CYP3A4 catalyzes N-demethylation of [14C]-erythromycin 
with subsequent formation of CO2, and therefore the metabolic activity of this enzyme may 
be expressed as the amount of the expired 14CO2 [Liu et al. 2007, Watkins 1994]. 
Similar breath tests detecting radiolabeled metabolites (or ratio of 14CO2 or 13CO2 to 12CO2) 
were designed for phynotyping CYP2C19 with use of [13C] pantoprazole [Furuta et al. 
2009], and CYP1A2 with the use of [14C] caffeine [Kalow & Tang 1993]. Multiple CYP 
metabolic activities (CYP2C19, 1A2, 3A4, and 2C9) were evaluated with [13C]- 
aminophenazone ("aminopyrine breath test") [Kodaira et al. 2011]. CYP2E1 activity in rats 
was measured using [14C] nitrosodimethylamine as a probe substrate [Bastien & 
Villeneuve 1998].  
2.5 Miotic response to opioids 
Significant correlations were observed between alfentanil pharmacokinetic parameters and 
its induced miotic kinetic parameters either under ambient or dark conditions. This means 
that pupillary response after alfentanil administration may be used as noninvasive measure 
of CYP3A4 metabolic activity [Baririan et al. 2005, Kharasch et al. 2004, Klees et al. 2005].  
O-demethylation of tramadol has been tried as a probe reaction for CYP2D6 phenotyping 
[Frank et al. 2007]. Pharmacokinetic parameters of its metabolite, O-demethyltramadol (M1) 
correlates well with pupillary constriction after tramadol administration. Since intrinsic 
efficacy of M1 is higher than of tramadol, higher pupillary constriction was observed in EM 
subjects [Slanar et al. 2007]. Interestingly, it was observed not only different patterns of 
miotic response between PM and EM groups, but also difference in the kinetic parameters 
(median time to reach max. miosis) between heterozygous and homozygous EM [Slanar et 
al. 2007]. It seems possible to discriminate EM from PM on the basis of the miotic response 
after tramadol administration [Slanar et al. 2007].  
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2.6 Cocktail approaches 
In early phase of drug development, there are utilized so called "high-throughput" methods 
increasing the efficiency and effectiveness of assay to assess metabolic activity of many CYP 
enzymes in short time [Smith et al. 2007, Testino & Patonay 2003, Zlokarnik et al. 2005]. 
Investigative methodologies for CYP enzymes often utilize so-called "cocktail" of markers to 
assess the metabolic activity of multiple CYP forms in one session [Asimus et al. 2007, Frye 
et al. 1997, Kumar et al. 2007, Smith et al. 2007, Tanaka et al. 2003, Yao, M. et al. 2007, Yao, 
Y.M. et al. 2007]. This approach is used either for in vivo or in vitro metabolic assessment. 
The markers of metabolic activity and their enzyme-specific metabolites can be assessed 
either simultaneously or separately [Blakey et al. 2004, Sharma et al. 2004]. A well known 
advantage of the cocktail approach is obtaining information of multiple CYP enzymes in a 
single experimental session [Tanaka et al. 2003]. Several different cocktails of markers have 
been used for this purpose (Table 6) [Asimus et al. 2007, Dierks et al. 2001, Sharma et al. 2004, 
Zhou et al. 2004]; as a "cocktail" is sometimes called any combination of at least 2 probe drugs, 
but generally from three up to six probes have been tried for in vivo CYP phenotyping [Zhou et 
al. 2004]. Among the most frequently used is e.g. "Pitsburgh cocktail": caffeine, chlorzoxazone, 
dapsone, debrisoquine, and mephenytoin for the combined assessment of  CYP1A2, CYP2E1, 
CYP2D6, CYP2C19, CYP3A and N-acetyltransferase activities [Zhou et al. 2004]. 
Unfortunately, the disadvantages of cocktail approach are also well defined: the frequent 
occurrence of adverse effects due to various pharmacodynamic-based interactions, more 
sample consumption (collection) for analysis and more complicated analytical methods 
[Tanaka et al. 2003]. After developing precise analytical methods, the cocktail approach 
became widely used and is now one of the basic analytical tools in early drug development (in 
vitro cocktails) [Zlokarnik et al. 2005]. Methods utilizing reaction with a marker and 
subsequent chromatographic analysis are recommended by the FDA in initial drug 
evaluations for investigating pharmacokinetic interactions with CYP enzymes [FDA 2006] (in 
contrast to some other high throughput methods). On the other hand, a "cocktail" approach 
can open a further question - can one marker influence the biotransformation rate of the other 
one? In some of these "cocktails", it was proved that the rates of biotransformation of single 
substrates are not affected by other drugs coadministered, but there are some examples that 
one probe substrate may affect the biotransformation rate of another one. Namely, there were 
reported an inhibition of midazolam metabolism by chlorzoxazone in humans [Palmer et al. 
2001], inhibition of nifedipine aromatization and sparteine dehydrogenation by quinidine in 
humans [Schellens et al. 1991], increase in phenacetin deethylation by tolbutamide in rats 
[Jurica et al. 2009]. Therefore, such assay may provide invalid (or at least inaccurate) results 
[Palmer et al. 2001]. Review of cocktails used in vivo is given in the Table 6. Except of these, 
only few other combinations of probe substrates have been used, e.g. assessment of CYP2A6 
metabolic activity (coumarin) with CYP2D6 (dextromethorphan) and CYP2C19 (mephenytoin) 
[Endres et al. 1996]. 
3. In vitro CYP activity assessment 
The specific probe substrates for CYP activity assessment and inhibition studies are used in 
the preclinical drug development as well as for clinical purpose. Research in this field is 
carried out on various models (human liver microsomes, recombinant CYP enzymes, 
hepatocytes, precision-cut human liver slices, organ perfusions etc.) which enables use of 
wide range of techniques and model substrates (e.g. luminometric, fluorometric,  
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Table 6. Probe substrate combinations for in vivo CYP activity assessment (adapted from 
[Tanaka et al. 2003, Zhou et al. 2004]) 
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radiolabeled etc.). In vitro methods are mostly used in preclinical drug development to 
predict possible CYP-mediated pharmacokinetic interactions. Unfortunately, there is a 
consensus that a prediction of in vivo interactions from in vitro data is not reliable. Moreover, 
as some authors hypothesize, in case of CYP3A4, any inductive or inhibitory effect observed 
in study with one probe CYP3A4 substrate can not accurately predict the extent of the in 
vivo interaction for another CYP3A4 substrate [Benet 2005]. FDA recommends suitable 
probe substrates for in vitro experiments in the drug development [FDA 2006]. These 
substrates are also mentioned in the appropriate tables below.  
3.1 Conventional probe substrates used in vitro 
3.1.1 CYP1A2 
Simple in vitro spectrophotometric methods like ethoxyresorufin O-deethylation (EROD) 
and methoxyresorufin O-demethylation (MROD) are frequently utilized in CYP1A 
metabolic activity assessment. These probe substrates were used in various models with 
liver microsomes from human, monkey, rat and mouse [FDA 2006, Hanioka et al. 2000, 
Chun et al. 1999]. Besides these, conventional probe substrates (registered drugs) are used in 
vitro as well (Table 7). 
 
Probe CYP1A2-specific reaction 
acetanilide C4- hydroxylation 
7-ethoxyresorufin O-deethylation 
7-methoxyresorufin O-demethylation 
caffeine N-demethylation 
phenacetine O-deethylation 
tacrine 1-hydroxylation 
theophylline N-demethylation 
Table 7. In vitro probes for CYP1A2 metabolic activity assessment [Henderson et al. 2000, 
Rendic 2002, Yuan et al. 2002] 
3.1.2 CYP2C9 
Despite that probe substrates are in general supposed to be highly specific and selective 
towards individual CYP forms, it was reported that with use of (S)-warfarin as a CYP2C9 
probe, significantly lower Ki values were obtained when compared to diclofenac, 
flurbiprofen, phenytoin or tolbutamide [Foti et al. 2010, Kumar et al. 2006]. Selective probe 
substrates for CYP2C9 in vitro activity assessment are summarized in the Table 8. 
3.1.3 CYP2C19 
Probe substrates for CYP2C19 activity assessment are summarized in the Table 9. As in the 
case of CYP2C9, also in CYP2C19 there were reported different sensitivities of probe 
substrates to inhibitors. (S)-mephenytoin was the most sensitive to a set of inhibitors when 
compared to (S)- or (R)-omeprazole or (S)-fluoxetine [Foti & Wahlstrom 2008, Foti et al. 
2010].  
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Probe CYP2C9-specific reaction 
celecoxib methyl hydroxylation 
diclofenac 4’-hydroxylation 
losartan oxidation 
naproxen O-demethylation 
Ppenytoin 4’-hydroxylation 
S-flurbiprofen 4’-hydroxylation 
S-warfarin 7-hydroxylation 
tolbutamide methylhydroxylation 
Table 8. In vitro probes for CYP2C9 metabolic activity assessment [Hummel et al. 2004, 
Rendic 2002, Tang et al. 2000, Yuan et al. 2002] 
 
Probe CYP2C19-specific reaction 
R-omeprazole 5-hydroxylation 
S-fluoxetine O-dealkylation 
S-mephenytoin 4'-hydroxylation 
S-omeprazole 5-hydroxylation 
Table 9. In vitro probes for CYP2C19 metabolic activity assessment [FDA 2006, Yuan et al. 
2002]  
3.1.4 CYP2D6  
In vitro CYP2D6 metabolic activity may be evaluated using the same substrates as in vivo. 
Except of these, bufuralol, and some fluorogenic probes were used to evaluate CYP2D6 
activity in vitro [Wang et al. 2009] (Table 10). Bufuralol is also metabolized via CYP2C19 
[Mankowski 1999] and CYP1A2 [Yamazaki et al. 1994], therefore its specificity for CYP2D6 
may be decreased. Nevertheless, bufuralol is the most preferred in vitro probe substrate (60 
% of in vitro studies) followed by dextromethorphan (30 % of in vitro studies) [Zhou 2009]. 
FDA recommends to use bufuralol, dextromethorphan or debrisoquine for in vitro 
experiments [FDA 2006]. 
 
Probe CYP2D6-specific reaction  
bufuralol 1-hydroxylation 
debrisoquine 4-hydroxylation 
carteolol C8-hydroxylation 
dextromethorphan O-demethylation 
metoprolol α-hydroxylation 
sparteine dehydrogenation 
tramadol  O-demethylation 
Table 10. In vitro probes for CYP2D6 metabolic activity assessment [FDA 2006, Frank et al. 
2007, Kudo & Odomi 1998, Rendic 2002, Zhou 2009] 
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3.1.5 CYP3A4 
Besides probe drugs used in vivo, some other conventional substrates are also used in vitro 
(listed in Table 11). As it was already mentioned above, it is strongly recommended to use at 
least 2 structurally urelated probe substrates for CYP3A4 meabolic activity evaluation. 
Standard inhibitors are used in preclinical drug development for evaluation of the inhibitory 
potency of new chemical entity or to identify individual CYP enzymes responsible for a 
drug’s metabolism, and to determine the relative contribution of an individual CYP enzyme 
to biotransformation of evaluated chemical entity (Table 12).  
 
Probe CYP3A4-specific reaction  
alfentanil demethylation 
alprazolam 4-hydroxylation 
benzyloxyresorufin  O-dealkylation 
cortisol 6-β hydroxylation 
cyclosporine oxidation 
dextromethorphan N-demethylation 
diazepam N-demethylation 
erythromycin N-demethylation 
ethylmorphine N-demethylation 
midazolam 1-hydroxylation 
nifedipine oxidation 
quinidine 3-hydroxylation /N-oxidation 
terfenadine C-hydroxylation 
testosterone 6-β hydroxylation 
triazolam 1-hydroxylation 
Table 11. In vitro probes for CYP3A4 metabolic activity assessment [FDA 2006, Meyer et al. 
2010, Yuan et al. 2002] 
 
CYP enzyme Inhibitor Ki (μM) 
CYP1A2 α-naphthoflavone 0.01 
 furafylline 0.6 - 0.73 
CYP2C9 fluconazole 7 
 fluvoxamine 6.4 - 19 
 fluoxetine 18 - 41 
 sulfaphenazole 0.3 
CYP2C19 nootkatone 0.5 
 ticlopidine 1.2 
CYP2D6 quinidine 0.027 - 0.4 
CYP3A4 itraconazole 0.27; 2.3 
 ketoconazole 0.0037 - 0.18 
Table 12. Inhibitors of CYP enzymes recommended by FDA for in vitro use (adapted from 
[FDA 2006]) 
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3.2 High throughput methods for CYP metabolic activity assays  
In past two decades, the role of in vitro drug metabolism and toxicity studies is slightly 
changing. Absorption, distribution, metabolism, excretion and toxicity studies (ADMET) 
have formerly been performed with a few compounds in the late stages of drug 
development. The number of compounds entering the drug discovery is increasing what 
requires to perform ADMET studies at earlier stages in the drug development [Atterwill & 
Wing 2002, Trubetskoy et al. 2005].  
Therefore, there is a need for new generation of assays with higher throughput capability, 
sensitivity and reproducibility. These assays are often automated and miniaturized. Plate-
scanning readers and handling robots, multi-channel analyzers, high-density assay plates 
together with automated LC-MS systems are mostly mentioned as the major support for 
such high throughput methods [Zlokarnik et al. 2005]. Thanks to these techniques, these 
approaches are also cheaper than standard procedures, maintaining sufficient selectivity, 
sensitivity and precision, and enable testing of large sets of compounds.  
3.2.1 Radiolabeled substrates 
Detection of 13/14C or 3H metabolites (H13/14CHO and/or 13/14CO2) of radiolabeled substrates 
(erythromycin, caffeine, cyclosporine, aminophenazone, diazepam etc. ) is used in some in 
vitro studies to assess metabolic activity of CYP3A4 [Grand et al. 2002, Kenworthy et al. 
1999]. Metabolites may be detected radiochemically, 14C-formaldehyde may be extracted 
and detected by radioluminescence in a microplate scintillation counter [Zlokarnik et al. 
2005]. In general, detection of radiolabeled substrates and metabolites seems to provide 
better limits of detection, accuracy and sensitivity than other conventional methods. Other 
advantage (over fluorogenic and luminogenic probe substrates) of this approach is ability to 
use common probe substrates with well known specificity, kinetic parameters and solubility 
[Zlokarnik et al. 2005]. 
3.2.2 Fluorogenic substrates 
Fluorogenic substrates are used in vitro very often. In general, these substrates are 
structurally modified fluorogenic compounds which are metabolized via various CYP forms 
to generate a fluorescent dye. These substrates are commercially available and widely used 
in preclinical drug development. Due to insufficient selectivity towards single CYP enzyme, 
these substrates are mostly used in recombinant CYP enzymes [Foti et al. 2010]. On the other 
hand, some of the fluorogenic substrates seem to be isoform-specific in lower 
concentrations, such as 3-O-methylfluorescein, which was evaluated for selectivity towards 
CYP2C19 [Sudsakorn et al. 2007].  
These difficulties are pronounced in many probe substrates - the most widely used 
fluorogenic substrate for assessment of CYP2C9 activity in vitro is 7-methoxy-4-
trifluoromethylcoumarin (MFC) [Crespi & Stresser 2000]. Despite this, some controversy 
about the selectivity of MFC towards CYP2C9 (the participation of several CYP enzymes in 
MFC O-demethylation) was also reported [Porrogi et al. 2008]. Nevertheless, MFC-based 
fluorometric CYP2C9 assays are described as "rapid with a high-throughput screening 
capacity, easy to perform, and amenable to automation" [Zhou et al. 2009]. Overview of 
fluorogenic substrates for individual CYP enzymes is given in the Table 13. 
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CYP enzyme Probe substrate Product / commercial name 
CYP1A2 3-cyano-7-ethoxycoumarin (CEC)  3-cyano-7-hydroxycoumarin 
(CHC) 
 7-ethoxy-methyloxy-3-cyanocoumarin (EOMCC) Vivid Blue 
CYP2C9 7-methoxy-4-(trifluoromethyl)-coumarin (7-
MFC)  
7-hydroxy-4-(trifluoromethyl)-
coumarin (HFC) 
 dibenzylfluorescein (DBF)  fluorescein 
 7-benzyloxy-methyloxy-3-cyanocoumarin 
(BOMCC)  
Vivid Blue 
 N-octyloxymethyl-resorufin (OOMR)  Vivid Red 
 benzyloxy-methyl-fluorescein (BOMF)  Vivid Green 
CYP2C19 3-cyano-7-ethyoxycoumarin (CEC) 3-cyano-7-hydroxycoumarin 
(CHC) 
 dibenzylfluorescein (DBF)  fluorescein 
 3-O-methylfluorescein (OMF)  fluorescein 
 7-ethoxy-methyloxy-3-cyanocoumarin (EOMCC) Vivid Blue 
CYP2D6 7-methoxy-4-(aminomethyl)-coumarin (MAMC) 7-hydroxy-4-(aminomethyl)-
coumarin (HAMC) 
 3-[2-(N,N diethyl-N-methylammonium)ethyl]-7-
methoxy-4-methylcoumarin (AMMC) 
3-[2-(diethylamino)-ethyl]-7-
hydroxy-4-methylcoumarin 
(AHMC) 
 7- p-methoxy-benzyloxy-4-trifluorocoumarin 
(MOBFC)  
Vivid Cyan 
 7-ethoxy-methyloxy-3-cyanocoumarin (EOMCC) Vivid Blue 
CYP3A4 7-benzyloxy-trifluoromethylcoumarin (BFC) 7-hydroxy-4-(trifluoromethyl)-
coumarin (HFC) 
 7-benzyloxyquinoline (7-BQ)  quinolinol 
 benzylresorufin  resorufin 
 di(benzyloxymethoxy)fluorescein (DBF)  fluorescein 
 benzyloxy-methyl-resorufin (BOMR)  Vivid Red 
 dibenzylmethylfluorescein (DBOMF)  Vivid Green 
 7-benzyloxy-methyloxy-3-cyanocoumarin 
(BOMCC)  
Vivid Blue 
 7-benzyloxy-methyloxy-4-(trifluoromethyl)-
coumarin (BOMFC)  
Vivid Cyan 
Table 13. Fluorogenic substrates for in vitro CYP enzyme activity assessment (adapted from 
Foti et. al. [FDA 2006, Foti et al. 2010]) 
Some of disadvantages (background fluorescence of unmetabolized substrate, low aqueous 
solubility, and low signal-to-noise ratio) which may limit the use of fluorescent substrates 
[Trubetskoy et al. 2005] were resolved by structurally related derivatives (e.g. 
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oxyphenylmethyl- , oxymethyl-, octyloxymethyl-) of commonly available substrates such as 
resorufin (red), coumarin (blue and cyan) and fluorescein (green). Currently (2011), there are 
available 8 modified fluorescent substrates for CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, CYP3A5 metabolic activities assessment [Makings & Zlokarnik 
2011]. Similarly to other common fluorogenic substrates, these derivatives were synthetized 
as "blocked" fluorophores with negligible background fluorescence (lower than in common 
fluorogenic probes). Fluorescence signal is triggered after isoenzyme specific 
biotransformation (Fig. 1) [Marks et al. 2003]. Moreover, these modified (Vivid®) substrates 
exhibit higher aqueous solubility and their molecule contains 2 potential cleavage sites 
[Marks et al. 2003]. Fluorogenic assays may be performed in miniaturized form in 
microplates. 
R2 H
O
R1
R2 OH
O
R1
 
phenolic dye
cytochrome P450
P450 oxidoreductase
NADPH
phenolic dye
++
spontaneous
phenolic dye (fluorescence)
alkyl products  
Fig. 1. Illustrative reaction of fluorescent CYP probe substrate (adapted from [Makings & 
Zlokarnik 2011].  
3.2.3 Luminometric substrates 
Luminometric substrate probes are used for CYP activity assessment since 2003. These 
probes are derivatives of luciferin, substrate for the firefly luciferase which generates light. 
The derivatives have to be metabolized by CYP enzymes to form luciferin prior to the 
reaction with luciferase and light emission [Cali et al. 2003]. Then, recorded luminiscence is 
proportional to the amount of metabolite what is dependent on activity of the CYP enzyme. 
Illustrative example of reaction is given in Figure 2.  
Various bioluminometric probe substrates (derivatives of luciferin) to test CYP1A1, 
CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, MAO-A and MAO-B activity are 
available. Luciferin 6´ chloroethyl ether (Luciferin –CEE) is a substrate for CYP1A1 and 
CYP1B1, luciferin 6´ methyl ether (Luciferin-ME) for CYP1A2 and CYP2C8, 6´ 
deoxyluciferin (luciferin-H) for CYP2C9, ethylene glycol ester of luciferin 6'-methyl ether 
(Luciferin-ME EGE) for CYP2D6, 6-deoxyluciferin ethyleneglycol ester (Luciferin-H EGE) 
for CYP2C19, luciferin 6´ benzyl ether (Luciferin –BE) and luciferin 6´ pentafluorobenzyl 
ether (Luciferin-PFBE) for CYP3A4 and CYP3A7, luciferin phenylpiperazine xylene ether 
(Luciferin-PPXE) and the latest one developed, luciferin isopropylacetal (Luciferin-IPA) 
for CYP3A4.  
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AMP + PPi
+CO2
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Luciferin-BE
Luciferin-H
luciferase
 
Fig. 2. Examples of CYP – mediated activation of luciferin (adapted from [Cali et al. 2011]) 
These methods may be also automated, miniaturized and used in "high-throughput" mode, 
in 3 or 6 µl 1536-well plates and low volume 384- well plates. The signal half-life of over 2 
hours enables batch processing of plates [Cali et al. 2008].  
4. Conclusion 
The selection of probe drug for either assessment of CYP metabolic activity in vitro or in vivo 
phenotyping is crucial for results of CYP metabolic activity assessment. Despite undeniable 
selectivity of probe substrates it seems that selection of distinct probe substrate may 
influence results obtained either in vitro or in vivo [Kumar et al. 2006, Stein et al. 1996]. The 
selection of appropriate probe drugs also depends on the system used - for in vivo 
phenotyping are used only conventional substrates (the registered drugs or endogenous 
substrate). A wide scale of substrates may be chosen for various in vitro systems such as 
human liver microsomes, recombinant CYP enzymes, hepatocytes, tissue slices and isolated 
organ perfusions. Conventional probe substrates mimics well the properties of other drugs, 
but the metabolites have to be analyzed by HPLC, mostly with MS, UV, fluorescence or 
electrochemical detection, or occasionally also with capillary electrophoretic methods 
[Konecny et al. 2007].  
In addition, in CYP3A4 it is recommended to use at least 2 structurally unrelated probe 
substrates because of presence of multiple substrate binding domains within CYP3A4 
protein [Khan et al. 2002, Korzekwa et al. 1998, Schrag & Wienkers 2001, Tucker et al. 2001]. 
Published crystal structures of CYP enzymes confirmed the ability of individual CYP 
enzyme to metabolize a wide range of substrates or to bind multiple substrate/inhibitor 
molecules simultaneously [Ekroos & Sjogren 2006, Foti et al. 2010].  
In some CYP forms, it seems that polymorphisms may have variable consequences in 
different substrates, as was shown in the case of CYP2D6 and CYP2C19. This phenomenon 
is also described as allele-dependent differences of substrates [Benet 2005]. In detail, this 
means that in the case of polymorphism CYP2D6*17, the rate of metabolism depends on the 
substrate used [Bogni et al. 2005, Zhou 2009].  
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Fluorogenic and bioluminometric probe substrates proved sufficiently their usability in 
early stages of drug development; these methods of CYP metabolic activity assessment are 
reproducible, robust and sensitive. On the other hand, since there is occasionally reported 
lack of correlation in specificity and sensitivity between fluorogenic and conventional 
probes (mostly in CYP3A4), follow-up studies with conventional probe substrates are 
strictly recommended to be performed in the clinical phase of new drug development 
[Cohen et al. 2003].  
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